Ms Parker remains on the board of directors. Ms Robinson joined Targeted Genetics in March 2000 and previously served as vice president of business development.
Prior to joining Targeted Genetics, Ms Robinson was director of business development at Genzyme Molecular Oncology, part of Genzyme. In her business development roles, she has completed multiple corporate and academic technology licenses, sponsored research agreements, and product development collaboration agreements.
Jeremy Cook, chairman of the board at Targeted Genetics, said: “On behalf of the board, I would like to express our genuine thanks to and esteem for Ms Parker and Dr Carter for their dedication and perseverance through some very gratifying and challenging times. We have full confidence in Ms Robinson and the rest of the team as we work to advance our valuable platform and product pipeline.”